Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans
José M. Vicencio(AstraZeneca (United Kingdom)), Tony Ng(King's College London)
Cited by 30
Related Papers
Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer
|Science Signaling|2014|166
Breast cancer–associated macrophages promote tumorigenesis by suppressing succinate dehydrogenase in tumor cells
|Science Signaling|2020|74
European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma
|Haematologica|2016|48
Chemotherapeutic regulation of the ROS/MondoA-dependent TXNIP/GDF15 axis; and derivation of a new organoid metric as a predictive biomarker
|bioRxiv (Cold Spring Harbor Laboratory)|2023|0